400-600-8767
13810794957@163.com
ICH Q1B 光穩(wěn)定性試驗（中英文）
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
ICH HARMONISED TRIPARTITE GUIDELINE
STABILITY TESTING: 穩(wěn)定性試驗
PHOTOSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
新原料藥和新制劑藥物的光穩(wěn)定性測試
Q1B
Current Step 4 version
現(xiàn)行版本第4步驟
dated 6 November 1996
1996年11月6日
This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA.
Q1B Document History 文件歷史
|
First Codification |
History |
Date |
New Codification November 2005 |
|
Q1B |
Approval by the Steering Committee under Step 2 and release for public consultation |
28 November 1995 |
Q1B |
Current Step 4 version
|
Q1B |
Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies |
6 November 1996 |
Q1B |
STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
新原料藥和新制劑藥物的光穩(wěn)定性測試
ICH Harmonised Tripartite Guideline
Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 6 November 1996, this guideline is recommended for adoption to the three regulatory parties to ICH
TABLE OF CONTENTS 目錄
1. General 概述......................................................................................................................1
A. Preamble 前言.............................................................................................................1
B. Light Sources 光源......................................................................................................2
C. Procedure 程序............................................................................................................2
2. Drug Substance 原料藥.......................................................................................................4
A. Presentation of Samples 樣品放置.....................................................................................4
B. Analysis of Samples 樣品分析............................................................................................5
C. Judgement of Results 結果判斷.........................................................................................5
3. Drug Product 制劑...........................................................................................................5
A. Presentation of Samples 樣品放置.....................................................................................6
B. Analysis of Samples 樣品分析............................................................................................6
C. Judgement of Results 結果判斷.........................................................................................6
4. Annex 附件.........................................................................................................................7
A. Quinine Chemical Actinometry 奎寧化學計量測試......................................................7
5. Glossary 術語.....................................................................................................................8
6. References 參考文獻................................................................................................................8
STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
Q1B 新原料藥和新制劑藥物的光穩(wěn)定性測試
1. GENERAL概述
The ICH Harmonized Tripartite Guideline covering the Stability Testing of New Drug Substances and Products (hereafter referred to as the Parent Guideline) notes that light testing should be an integral part of stress testing. This document is an annex to the Parent Guideline and addresses the recommendations for photostability testing.
新原料藥和新藥制劑的ICH穩(wěn)定性試驗指導原則（以下稱總指導原則）指出光照試驗是強力破壞試驗中的重要組成部分。本文是總指導原則的附加說明，提出了光穩(wěn)定性試驗的一些建議。
A. Preamble前言
The intrinsic photostability characteristics of new drug substances and products should be evaluated to demonstrate that, as appropriate, light exposure does not result in unacceptable change. Normally, photostability testing is carried out on a single batch of material selected as described under Selection of Batches in the Parent Guideline. Under some circumstances these studies should be repeated if certain variations and changes are made to the product (e.g., formulation, packaging). Whether these studies should be repeated depends on the photostability characteristics determined at the time of initial filing and the type of variation and/or change made.
新原料藥和新藥制劑應經過適當的光穩(wěn)定特征考察，證明其本身的光穩(wěn)定性，即光照不能引起不可接受的變化。按照總指導原則中“批號選擇”，光穩(wěn)定性試驗只須選做一批樣品。在某些情況下如當這個產品發(fā)生變更或變化時（如處方、包裝），這些研究應再重復進行。這些研究是否必須重復進行取決于初次申報文件中所測定的該物質的光穩(wěn)定特征及變更或變化的類型。
The guideline primarily addresses the generation of photostability information for submission in Registration Applications for new molecular entities and associated drug products. The guideline does not cover the photostability of drugs after administration (i.e. under conditions of use) and those applications not covered by the Parent Guideline. Alternative approaches may be used if they are scientifically sound and justification is provided.
本指導原則主要闡述注冊申報新化合物及其制劑時所需報送的光穩(wěn)定性試驗資料，不包括給藥后（即使用中的）的光穩(wěn)定性試驗和總指導原則中未包括其用法的藥物的申報內容。如果有科學合理的其他替代方法也可采用。
A systematic approach to photostability testing is recommended covering, as appropriate, studies such as:
建議光穩(wěn)定性試驗研究包括：
i) Tests on the drug substance;
I. 原料藥光穩(wěn)定性測試
ii) Tests on the exposed drug product outside of the immediate pack; and if necessary ;
II. 對除去內包裝的制劑試驗（如需要）；
iii) Tests on the drug product in the immediate pack; and if necessary ;
III. 對除去外包裝的制劑試驗（如需要）；
iv) Tests on the drug product in the marketing pack.
IV. 上市包裝的制劑試驗。
The extent of drug product testing should be established by assessing whether or not acceptable change has occurred at the end of the light exposure testing as described in the Decision Flow Chart for Photostability Testing of Drug Products. Acceptable change is change within limits justified by the applicant. The formal labeling requirements for photolabile drug substances and drug products are established by national/regional requirements.
按判斷圖指示進行藥物光穩(wěn)定性試驗，可根據到哪一步發(fā)生了可以接受的變化來決定試驗到哪一步即可停止，“可接受的變化”是指經申報者論證合理的限度內的變化。光敏性藥物和制劑是否要在標簽上標記要求，由國家和地區(qū)確定。
B. Light Sources 光源
The light sources desc ribed below may be used for photostability testing. The applicant should either maintain an appropriate control of temperature to minimize the effect of localized temperature changes or include a dark control in the same environment unless otherwise justified. For both options 1 and 2, a pharmaceutical manufacturer/applicant may rely on the spectral distribution specification of the light source manufacturer.
以下描述的光源可以用于光穩(wěn)定性測試。申報者應該對溫度進行適當的控制，以降低溫度對該檢測的影響或者是在相同的環(huán)境下進行暗度控制（避光對照），如有另有說明者除外。不管選擇1還是2，藥劑生產者或者申報者均可以采用光源生產商所給定的光譜分布規(guī)格數據。
Option 1
Any light source that is designed to produce an output similar to the D65/ID65 emission standard such as an artificial daylight fluorescent lamp combining visible and ultraviolet (UV) outputs, xenon, or metal halide lamp. D65 is the internationally recognized standard for outdoor daylight as defined in ISO 10977 (1993). ID65 is the equivalent indoor indirect daylight standard. For a light source emitting significant radiation below 320 nm, an appropriate filter(s) may be fitted to eliminate such radiation.
選擇1：
采用任何輸出相似于D65／ID65 發(fā)射標淮的光源，如具有可見光和紫外光輸出的人造日光熒光燈、 氙燈或金屬鹵化物燈。D65 是國際上認可的室外日光標準，在1993年的ISO10977中對此進行了規(guī)定，ID65是相當于室內間接日光光照的標準。光源發(fā)射光低于320nm時，應當配備適當的裝置去濾除此光。
Option 2 選擇2
For option 2 the same sample should be exposed to both the cool white fluorescent and near ultraviolet lamp.
對于本選擇，應使用相同的樣品同時采用于冷白熒光燈和近紫外熒光燈照射。
1. A cool white fluorescent lamp designed to produce an output similar to that specified in ISO 10977(1993) ; and
冷白熒光燈應具有與ISO10977（1993）中規(guī)定的輸出功率
2. A near UV fluorescent lamp having a spectral distribution from 320 nm to 400 nm with a maximum energy emission between 350 nm and 370 nm; a significant proportion of UV should be in both bands of 320 to 360 nm and 360 to 400 nm.
近紫外熒光燈可以發(fā)射的光線在320~400nm，在350~370nm有一個最大的能量發(fā)射；紫外線的重要組成部分應當是在320~360nm，和360~400nm的范圍內
C. Procedure規(guī)程
For confirmatory studies, samples should be exposed to light providing an overall illumination of not less than 1.2 million lux hours and an integrated near ultraviolet energy of not less than 200 watt hours/square meter to allow direct comparisons to be made between the drug substance and drug product.
在確認研究中，樣品應暴露在總照度不低于1.2×106Lux.hr，近紫外能量不低于200w.hr/m2，直接在藥物和制劑之間進行比較。
Samples may be exposed side-by-side with a validated chemical actinometric system to ensure the specified light exposure is obtained, or for the appropriate duration of time when conditions have been monitored using calibrated radiometers/lux meters. An example of an actinometric procedure is provided in the Annex.
樣品可與經論證過的光化強度系統(tǒng)并排暴露于有效的光化強度下，以確保獲得指定的光暴露，或在用經校正的測光儀或照度儀監(jiān)測的條件下，持續(xù)相當的時間。附錄中提供了光化強度測定方法的例子。
If protected samples (e.g., wrapped in aluminum foil) are used as dark controls to evaluate the contribution of thermally induced change to the total observed change, these should be placed alongside the authentic sample.
若用遮光對照樣品（如用鋁箔包裝）作為暗度控制來考察由熱引起的變化對總變化的影響，應使其與真實樣品并排放置。
注解：Lux：勒克斯，亮度單位，在英國叫做尺光度，在歐洲叫做lux，具體來說1勒克斯相當于一只蠟燭從1米外投射在一平方米的表面上的光的數量。
DECISION FLOW CHART FOR PHOTOSTABILITY TESTING OF DRUG PRODUCTS
藥物光穩(wěn)定性測試流程示意圖
2. DRUG SUBSTANCE 原料藥
For drug substances, photostability testing should consist of two parts: forced degradation testing and confirmatory testing.
對于原料藥，光穩(wěn)定性測試包括兩個方面的內容：強制的降解試驗和確認性試驗
The purpose of forced degradation testing studies is to evaluate the overall photosensitivity of the material for method development purposes and/or degradation pathway elucidation. This testing may involve the drug substance alone and/or in simple solutions/suspensions to validate the analytical procedures. In these studies, the samples should be in chemically inert and transparent containers. In these forced degradation studies, a variety of exposure conditions may be used, depending on the photosensitivity of the drug substance involved and the intensity of the light sources used. For development and validation purposes it is appropriate to limit exposure and end the studies if extensive decomposition occurs. For photostable materials, studies may be terminated after an appropriate exposure level has been used. The design of these experiments is left to the applicant’s discretion although the exposure levels used should be justified.
強制降解試驗研究的目的是對藥物的總的光敏性進行研究評價，以建立測試方法和說明降解路徑。強制降解試驗對象包括藥物本身和（或）它的簡單的溶液或混懸液，以確證分析方法。在這些研究中，樣品應盛裝在化學惰性的透明容器中。強制降解研究中可能使用各種暴露條件，這取決于藥物本身的光敏性和所使用的光源強度。在建立和論證（方法）時，如發(fā)生大量分解，即可限制暴露和中止研究。對于光穩(wěn)定性物質，在適當的光暴露后即可以中止研究。雖然采用的暴露水平是應經論證的，但試驗設計可由申報者自己定。
Under forcing conditions, decomposition products may be observed that are unlikely to be formed under the conditions used for confirmatory studies. This information may be useful in developing and validating suitable analytical methods. If in practice it has been demonstrated they are not formed in the confirmatory studies, these degradation products need not be further examined.
在強制條件下，可能會觀察到在確認研究條件下不易生成的分解產物，這一信息對建立和論證分析方法是有用的。如果實際證明這些降解產物在確認研究中并不會產生，就不必對它們進一步實驗。
Confirmatory studies should then be undertaken to provide the information necessary for handling, packaging, and labeling (see section I.C., Procedure, and II.A., Presentation, for information on the design of these studies).
接著進行確認研究以提供處理、包裝、標簽等所需要的信息（設計這些研究所需的信息，見1.C方法和IIA樣品放置）
Normally, only one batch of drug substance is tested during the development phase, and then the photostability characteristics should be confirmed on a single batch selected as described in the Parent Guideline if the drug is clearly photostable or photolabile. If the results of the confirmatory study are equivocal, testing of up to two additional batches should be conducted. Samples should be selected as described in the Parent Guideline.
一般說來，在研制階段只需測試一批樣品，如果原料藥明顯光穩(wěn)定或光不穩(wěn)定，可以根據指導原則選擇一批樣品來確定光穩(wěn)定性特征。如果確認結果不明確，應加試兩個批號的樣品，樣品選擇應符合總指導原則。
A. Presentation of Samples 樣品的放置
Care should be taken to ensure that the physical characteristics of the samples under test are taken into account and efforts should be made, such as cooling and/or placing the samples in sealed containers, to ensure that the effects of the changes in physical states such as sublimation, evaporation or melting are minimized. All such precautions should be chosen to provide minimal interference with the exposure of samples under test. Possible interactions between the samples and any material used for containers or for general protection of the sample, should also be considered and eliminated wherever not relevant to the test being carried out.
應充分考慮受試樣品的物理性質，采取措施如冷藏和&或置密閉容器中，以確保物理狀態(tài)變化如升華、蒸發(fā)、熔化所造成的影響為最小。應采取各種預防措施使供試品光照時少受其他因素的影響。無論與進行的試驗有無關系，都應考慮并排除樣品與包裝材料之間可能存在的相互反應。
As a direct challenge for samples of solid drug substances, an appropriate amount of sample should be taken and placed in a suitable glass or plastic dish and protected with a suitable transparent cover if considered necessary. Solid drug substances should be spread across the container to give a thickness of typically not more than 3 millimeters. Drug substances that are liquids should be exposed in chemically inert and transparent containers.
固體原料藥的樣品，應取適量放在適宜的玻璃或塑料碟中，必要時以適宜的透明蓋子保護。固體藥物應分散在容器中，厚度不超過3毫米。液體藥物應存放在化學惰性的透明容器中。
B. Analysis of Samples 樣品分析
At the end of the exposure period, the samples should be examined for any changes in physical properties (e.g., appearance, clarity, or color of solution) and for assay and degradants by a method suitably validated for products likely to arise from photochemical degradation processes.
光照時間一到，就要檢查樣品是否有物理性質（如外觀、溶液的顏色或澄清度）、含量和降解物的變化。用一種經論證可以檢測出光降解物質的合理方法，測定光化反應降解產生的降解物質。
Where solid drug substance samples are involved, sampling should ensure that a representative portion is used in individual tests. Similar sampling considerations, such as homogenization of the entire sample, apply to other materials that may not be homogeneous after exposure. The analysis of the exposed sample should be performed concomitantly with that of any protected samples used as dark controls if these are used in the test.
對于固體原料藥，取樣應確保在每一項試驗中所用的樣品具代表性。對于光照后可能會不均勻的物質，取樣時需考慮整個樣品的均勻化。如果試驗中有用于暗度控制研究的樣品（可用各種方法將樣品保護起來不受光照），則應與光照過的樣品同時測定。
C. Judgement of Results 結果判定
The forced degradation studies should be designed to provide suitable information to develop and validate test methods for the confirmatory studies. These test methods should be capable of resolving and detecting photolytic degradants that appear during the confirmatory studies. When evaluating the results of these studies, it is important to recognize that they form part of the stress testing and are not therefore designed to establish qualitative or quantitative limits for change.
“強制降解”研究應設計成能為建立和論證“確認研究”的試驗方法提供適當的信息。這些試驗方法應能分辨和檢測確認研究中出現(xiàn)的光降解物質。在評價這些研究結果時，重要的是應考慮到他們是組成強力破壞試驗的一部分，而并不是設計成去建立這些變化的定量和定性限度。
The confirmatory studies should identify precautionary measures needed in manufacturing or in formulation of the drug product, and if light resistant packaging is needed. When evaluating the results of confirmatory studies to determine whether change due to exposure to light is acceptable, it is important to consider the results from other formal stability studies in order to assure that the drug will be within justified limits at time of use (see the relevant ICH Stability and Impurity Guidelines).
確認研究應提供生產和制劑處方中所必要的預防措施，是否需要避光包裝。當評估確認研究的結果以決定光照所引起的變化是否可接受時，必須同時考慮其他正式的穩(wěn)定性研究結果，以確保藥物在使用期內符合合理范圍。（見ICH 穩(wěn)定性及雜質指導原則）
3. DRUG PRODUCT制劑藥物
Normally, the studies on drug products should be carried out in a sequential manner starting with testing the fully exposed product then progressing as necessary to the product in the immediate pack and then in the marketing pack. Testing should progress until the results demonstrate that the drug product is adequately protected from exposure to light. The drug product should be exposed to the light conditions described under the procedure in section I.C.
通常對制劑的研究應進行一系列試驗，首先制劑應完全暴露進行試驗，如有必要，再以內包裝進行試驗，最后以上市包裝進行試驗。試驗一直做到結果證明在光照下藥物也受到了足夠的保護。制劑應按1.C 章節(jié)中所描述的方法進行光照試驗。
Normally, only one batch of drug product is tested during the development phase, and then the photostability characteristics should be confirmed on a single batch selected as described in the Parent Guideline if the product is clearly photostable or photolabile. If the results of the confirmatory study are equivocal, testing of up to two additional batches should be conducted.
一般來說，在開發(fā)研究階段，只測試一批樣品，如果產品對光穩(wěn)定或不穩(wěn)定表現(xiàn)明顯，則光穩(wěn)定試驗應按照總指導原則所描述的方法選擇一個批號進行；如果確認研究結果比較含糊，應再試驗兩批以上的樣品。
For some products where it has been demonstrated that the immediate pack is completely impenetrable to light, such as aluminium tubes or cans, testing should normally only be conducted on directly exposed drug product.
對有些制劑已證明其內包裝完全避光，如鋁管或鋁罐，一般只需做制劑的直接暴露試驗。
It may be appropriate to test certain products such as infusion liquids, dermal creams, etc., to support their photostability in-use. The extent of this testing should depend on and relate to the directions for use, and is left to the applicant’s discretion.
有些制劑如輸液、皮膚用霜劑等，應做一些試驗證明其使用時的光穩(wěn)定性。試驗的程度取決于使用方式，由申報者自行考慮。
The analytical procedures used should be suitably validated.
所有分析方法應經合適的論證。
A. Presentation of Samples樣品的放置
Care should be taken to ensure that the physical characteristics of the samples under test are taken into account and efforts, such as cooling and/or placing the samples in sealed containers, should be made to ensure that the effects of the changes in physical states are minimized, such as sublimation, evaporation, or melting. All such precautions should be chosen to provide a minimal interference with the irradiation of samples under test. Possible interactions between the samples and any material used for containers or for general protection of the sample should also be considered and eliminated wherever not relevant to the test being carried out.
應認真考慮受試樣品的物理性質，例如采取措施如冷藏和(或置密閉容器中，以確保物理狀態(tài)變化如升華、蒸發(fā)、熔化所造成的影響為最小。預先應采取必要措施，使受試樣品少受這些因素的影響。無論與進行的試驗有無關系，都應考慮并排除樣品與包裝材料之間可能存在的相互反應。
Where practicable when testing samples of the drug product outside of the primary pack, these should be presented in a way similar to the conditions mentioned for the drug substance. The samples should be positioned to provide maximum area of exposure to the light source. For example, tablets, capsules, etc., should be spread in a single layer.
除去包裝的受試樣品放置條件應與原料藥條件相似，保證受到最大面積的光照，如片劑、膠囊劑應分散為單層。
If direct exposure is not practical (e.g., due to oxidation of a product), the sample should be placed in a suitable protective inert transparent container (e.g., quartz).
如果直接暴露不可行（如由于藥品易氧化），樣品應放在合適的惰性透明容器中（如石英容器）。
If testing of the drug product in the immediate container or as marketed is needed, the samples should be placed horizontally or transversely with respect to the light source, whichever provides for the most uniform exposure of the samples. Some adjustment of testing conditions may have to be made when testing large volume containers (e.g., dispensing packs).
若樣品需在內包裝或在上市包裝的條件下進行試驗，樣品應水平放置或橫面對光源，以保證樣品得到最大均勻的光照，當試驗大體積容器包裝的樣品時，有些試驗條件應調整（如分散包裝）。
B. Analysis of Samples樣品的分析
At the end of the exposure period, the samples should be examined for any changes in physical properties (e.g., appearance, clarity or color of solution, dissolution/disintegration for dosage forms such as capsules, etc.) and for assay and degradants by a method suitably validated for products likely to arise from photochemical degradation processes.
光照結束后，應檢查樣品的所有物理性質（如：外觀、溶液的澄清度或顏色、固體制劑如膠囊劑等的溶解度或崩解度）的變化并進行含量、降解產物測定。所采用的分析方法應經過論證，可證實它適合檢出光化學降解過程中所生成的物質。
When powder samples are involved, sampling should ensure that a representative portion is used in individual tests. For solid oral dosage form products, testing should be conducted on an appropriately sized composite of, for example, 20 tablets or capsules. Similar sampling considerations, such as homogenization or solubilization of the entire sample, apply to other materials that may not be homogeneous after exposure (e.g., creams, ointments, suspensions, etc.). The analysis of the exposed sample should be performed concomitantly with that of any protected samples used as dark controls if these are used in the test.
對于粉末狀樣品，取樣時應確保每一份測定的供試品具有代表性。對固體口服制劑，應取合適的量，如片劑或膠囊20 片或粒。對光照后可能不均一的樣品（如霜劑、軟膏、混懸劑）也同樣應考慮其采樣的代表性問題，如對整個樣品進行均勻化或溶解增溶。如果有暗度控制的樣品，則光照的樣品應與這些保護性樣品同時進行分析。
C. Judgement of Results結果判定
Depending on the extent of change special labeling or packaging may be needed to mitigate exposure to light. When evaluating the results of photostability studies to determine whether change due to exposure to light is acceptable, it is important to consider the results obtained from other formal stability studies in order to assure that the product will be within proposed specifications during the shelf life (see the relevant ICH Stability and Impurity Guidelines).
根據變化的程度，可采用特殊標簽或包裝來限制儲藏中的樣品的光照。當評估光穩(wěn)定性試驗結果以確定由光照引起何種程度的變化是可接受時，必須綜合考慮其他正式穩(wěn)定性研究的結果，以確保藥品在貨架壽命產品會一直在規(guī)定的規(guī)格范圍之內。（見ICH穩(wěn)定性和雜質指導原則）
4. ANNEX附件
A. Quinine Chemical Actinometry
The following provides details of an actinometric procedure for monitoring exposure to a near UV fluorescent lamp (based on FDA/National Institute of Standards and Technology study). For other light sources/actinometric systems, the same approach may be used, but each actinometric system should be calibrated for the light source used.
Prepare a sufficient quantity of a 2 per cent weight/volume aqueous solution of quinine monohydrochloride dihydrate (if necessary, dissolve by heating).
A. 奎寧的光化強度
以下詳細介紹監(jiān)控暴露在近UV, 熒光燈（根據FDA/國家標準和技術研究所）下的光化強度方法。對其他光源/ 光化體系，也可使用相同的方法，但各光化系統(tǒng)均應根據所采用的光源作校正。
準備足量的2%（W/V）鹽酸奎寧二水合物的水溶液（必要時加熱溶解）。
Option 1
Put 10 milliliters (ml) of the solution into a 20 ml colorless ampoule seal it hermetically, and use this as the sample. Separately, put 10 ml of the solution into a 20 ml colourless ampoule (see note 1), seal it hermetically, wrap in aluminum foil to protect completely from light, and use this as the control. Expose the sample and control to the light source for an appropriate number of hours. After exposure determine the absorbances of the sample (AT) and the control (Ao) at 400 nm using a 1 centimeter (cm) path length. Calculate the change in absorbance, Δ A = AT - Ao. The length of exposure should be sufficient to ensure a change in absorbance of at least 0.9.
方法1
將10ml溶液置20ml無色安瓿中，密封，以此作為樣品；另將10ml 溶液置20ml無色安瓿（見注1）密封，包鋁箔避光，作為對照；將上述兩安瓿于光源中光照數小時后，在400nm波長處，用1cm石英池測定樣品吸收度（At）和對照品吸收度（Ao），計算△A=At-Ao。光照時間應足夠，確?！?/span>A 不小于0.9。
Option 2
Fill a 1 cm quartz cell and use this as the sample. Separately fill a 1 cm quartz cell, wrap in aluminum foil to protect completely from light, and use this as the control. Expose the sample and control to the light source for an appropriate number of hours. After exposure determine the absorbances of the sample (AT) and the control (Ao) at 400 nm. Calculate the change in absorbance, Δ A = AT - Ao. The length of exposure should be sufficient to ensure a change in absorbance of at least 0.5.
Alternative packaging configurations may be used if appropriately validated. Alternative validated chemical actinometers may be used.
方法2：
將溶液加到一個1cm的石英池中，將其作為樣品。另外，將溶液加入到一個1cm的石英池中，將其包在鋁薄中以保證完全避免光照，將其作為對照樣品。在一定的時間段內，將檢測樣品和對照樣品暴露在光照下，光照會影響到樣品和對照樣品的吸收度，計算二者吸收度的變化，△A=AT-Ao。光照時間應足夠，確?！?/span>A不小于0.5。
如果經過了驗證，其他包裝結構也可以使用?？墒褂闷渌浾撟C的光化線測量儀。
Note 1: Shape and Dimensions (See Japanese Industry Standard (JIS) R3512 (1974) for ampoule specifications)
注釋一：安瓿的形狀和直徑（參考日本工業(yè)標準（JLS）R3512（1974）中的特定安瓿）
5. GLOSSARY名詞解釋
Immediate (primary) pack is that constituent of the packaging that is in direct contact with the drug substance or drug product, and includes any appropriate label.
內包裝指包裝中直接接觸原料藥或制劑的包裝，包括任何適當的標簽。
Marketing pack is the combination of immediate pack and other secondary packaging such as a carton.
上市包裝指內包裝和其他層次包裝（如紙盒）的總和。
Forced degradation testing studies are those undertaken to degrade the sample deliberately. These studies, which may be undertaken in the development phase normally on the drug substances, are used to evaluate the overall photosensitivity of the material for method development purposes and/or degradation pathway elucidation.
強制降解試驗研究指有意地使樣品降解的實驗，這些研究一般在原料藥處于開發(fā)階段時進行，用于評價藥物的總光敏性，以建立測試方法和（或）說明降解途徑。
Confirmatory studies are those undertaken to establish photostability characteristics under standardized conditions. These studies are used to identify precautionary measures needed in manufacturing or formulation and whether light resistant packaging and/or special labeling is needed to mitigate exposure to light. For the confirmatory studies, the batch(es) should be selected according to batch selection for long-term and accelerated testings which is described in the Parent Guideline.
確認研究指在標準化條件下確立一個光穩(wěn)定性特征的實驗研究，這些研究用于指導生產工藝是否采取保護性措施，以及決定是否采用避光包裝或特使標簽來保護藥品減少光照。確認研究的樣品批號選擇應根據總指導原則所規(guī)定的長期和加速試驗的批號選擇。
6. REFERENCES參考書
Quinine Actinometry as a method for calibrating ultraviolet radiation intensity in light-stability testing of pharmaceuticals. 藥劑光穩(wěn)定性測試中用奎寧感光法來校正紫外輻射強度。
Yoshioka S. et al., Drug Development and Industrial Pharmacy, 20 (13), 2049 - 2062 (1994).
Yoshioka S.et al., 藥劑研發(fā)和工業(yè)生產，20（13），2049～2062（1994）
蘭貝石藥品強光照射試驗箱符合以上法規(guī)要求，并加入了照度的存儲打印功能
